🚀Enjoy a 7-Day Free Trial Until Jul 19, 2024!

HL

Hillevax IncNASDAQ HLVX Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is HLVX undervalued compared to its fair value?

The fair value of HLVX stock is hidden USD. Relative to the market price of 1.75 USD Hillevax Inc is hidden.

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for t...[More about valuation]

Hillevax Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.083 $B

Price:

1.75 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.815

FINANCIALS

Hillevax financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.034 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.032 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.37 B
0.3 B

Financial Position Analysis

Assets

0.37 B
Current Assets
0.33 B
Total non-current assets
0.034 B

Total current liabilities
0.019 B
Total non-current liabilities
0.049 B

Cash Flow Statement

-0.029 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.027 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Hillevax fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is HLVX attractive for investment based on fundamental analysis?

HLVX stock rating is hidden. Hillevax is a hidden by Eyestock methodology.

Get HLVX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

HLVX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for HLVX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Hillevax Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Hillevax Inc dividends

HLVX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About HLVX stock

About the company Hillevax Inc

Market cap $B

0.083

Dividend yield

Shares outstanding

37.656037 B

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4.

HLVX profile

  • Ticker

    HLVX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    29 April 2022

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    31

  • City

    Boston

  • Address

    75 State St., Suite 100

  • Cusip

    43157M102